Company / Named in our posts
Lyell Immunopharma, Inc..
Follow Lyell Immunopharma, Inc.A clinical-stage T-cell reprogramming company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies.[1]
01Deal
Deals on Carrywatch
Every deal that names Lyell Immunopharma, Inc., and its role in each.
Lyell Immunopharma, Inc. / ImmPACT Bio USA Inc.
Lyell Immunopharma completes ImmPACT Bio acquisition
See deal detailsDeal Web
Lyell Immunopharma, Inc. and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
5 fiscal years of figures as Lyell Immunopharma, Inc. reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01EX-99.1 — Lyell Immunopharma Completes Acquisition of ImmPACT Bio
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02Form 8-K — Lyell Immunopharma, Inc.
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Lyell Immunopharma, Inc.:
- P01